Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan.

Multiple Cancer Types

Pediatrics, Sarcoma
N/A
Friedman, Debra
VICCPED2222

Expanded Access to Trametinib for a child with Plexiform Neurofibroma in NF1

Pediatrics

Pediatrics
N/A
Esbenshade, Adam
VICCPED2251

NN7999-3895: Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B

Hematologic

Hematologic
III
Wheeler, Allison
NCT02141074
VICCNCBH1756

Renal Tumors Classification, Biology, and Banking Study

Multiple Cancer Types

Pediatrics, Wilms / Other Kidney (Pediatrics)
N/A
Benedetti, Daniel
NCT00898365
COGAREN03B2

Neuroblastoma Biology Studies

Multiple Cancer Types

Neuroblastoma (Pediatrics), Pediatrics
N/A
Benedetti, Daniel
NCT00256763
CCGANBL00B1

Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Pediatrics

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients who have rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines the effect of therapy intensification in patients who have RMS cancer with DNA mutations to see if their outcomes can be improved.
Pediatrics
III
Borinstein, Scott
NCT05304585
COGARST2032

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Multiple Cancer Types

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to
identify a recommended dose of bosutinib administered orally once daily in pediatric patients
with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who
have received at least one prior TKI therapy (R/I CML), to preliminary estimate the safety
and tolerability and efficacy, and to evaluate the PK of bosutinib in this patient
population.
Pediatric Leukemia, Pediatrics
I/II
Zarnegar-Lumley, Sara
NCT04258943
COGAAML1921

Conditioning SCID Infants Diagnosed Early

Multiple Cancer Types

The investigators want to study if lower doses of chemotherapy will help babies with SCID to
achieve good immunity with less short and long-term risks of complications after
transplantation. This trial identifies babies with types of immune deficiencies that are most
likely to succeed with this approach and offers them transplant early in life before they get
severe infections or later if their infections are under control. It includes only patients
receiving unrelated or mismatched related donor transplants.

The study will test if patients receiving transplant using either a low dose busulfan or a
medium dose busulfan will have immune recovery of both T and B cells, measured by the ability
to respond to immunizations after transplant. The exact regimen depends on the subtype of
SCID the patient has. Donors used for transplant must be unrelated or half-matched related
(haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance
of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T
cells removed, using a newer, experimental approach of a well-established technology. Once
the stem cell transplant is completed, patients will be followed for 3 years. Approximately
9-18 months after the transplant, vaccinations will be administered, and a blood test
measuring whether your child's body has responded to the vaccine will be collected.
Hematologic, Pediatrics
II
Connelly, James
NCT03619551
VICCNCPED18122

A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT

Multiple Cancer Types

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patients response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Germ Cell (Pediatrics), Pediatrics
II
Esbenshade, Adam
NCT04684368
COGACNS2021

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Multiple Cancer Types

This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Pediatric Solid Tumors, Pediatrics
I/II
Borinstein, Scott
NCT05071209
COGPEPN2112

To learn more about any of our clinical
trials, call 615-936-8422.